From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Interview with Ashley Frith, MD: Early-Stage Disease Research Highlights from the 2025 San Antonio Breast Cancer Symposium

View all
FROM THE EDITORS

Welcome to the HR+ HER2– Breast Cancer Resource Center! We are pleased to offer a curated selection of current information, practice advancements, literature highlights, and professional resources focused on this clinical area. Our goal is to support advanced practitioners in their critical role of providing evidence-based, high-quality care to patients.

For any questions, comments, suggestions or to request information on a specific topic, please contact us at jadpro-editor@conexiant.com.

 

 

Katie Newlin, Katie Newlin, RN, MSN, AGPCNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

 

Lisa Salem, MSN, FNP-BC, AOCNP

Washington University in St. Louis/Siteman Cancer Center

Resources

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

Real-world Risk of Recurrence by Nodal Status in Patients with HR+, HER2-, Node-positive, High-Risk Early Breast Cancer

Oral Chemotherapy Education

Intravenous Cancer Treatment Education

NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE)

News & Literature Highlights

Future Oncology

OPERA-01: A phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapy

Cancers

The prognostic and predictive value of body mass index in patients with HR+/HER2- breast cancer treated with CDK4/6 inhibitors: A systematic literature review

Breast Cancer Research

Multiomic profiling of ER-positive HER2-negative breast cancer reveals markers associated with metastatic spread

Cancer Research and Treatment

Pre-treatment Ki67 index for everolimus efficacy in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer: A multicenter cohort study

Journal of Surgical Oncology

Do racial and income disparities exist in the application of 21-gene recurrence score?

JAMA Oncology

Vaginal estrogen therapy use and survival in females with breast cancer

Journal of Clinical Oncology

Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial

Cancers

CDK4/6 inhibitors plus endocrine therapy in early-stage HR+/HER2- breast cancer: Updated meta-analysis of phase III trials

American Medical Journal

Updates in advanced hormone receptor-positive breast cancer: From circulating tumor DNA-guided therapy to precision medicine

Journal of Clinical Oncology

Elacestrant combinations in patients (pts) with ER+/HER2- locally advanced or metastatic breast cancer (mBC): Safety update from ELEVATE, a phase (Ph) 1b/2, open-label, umbrella study

Advertisement
Case Studies

Navigating Treatment Adherence in Early-Stage Breast Cancer

Isolated Brain Metastasis in BRCA2-Mutated HR+ HER2- Breast Cancer

Genetic Testing and Risk Intervention Based on Family History of Early-Onset Breast Cancer

Advertisement
Quizzes
Test your knowledge of treatment adherence in early-stage breast cancer
Test your knowledge of isolated brain metastasis in BRCA2-mutated HR+ HER2- breast cancer
Test your knowledge of genetic testing and risk intervention based on family history of early-onset breast cancer